Jorgensen Nathan D. 4

4 · Voyager Therapeutics, Inc. · Filed Feb 10, 2026

AI-generated summary of this filing

Updated Feb 10, 2026

Voyager (VYGR) CFO Nathan Jorgensen Receives RSUs & Stock Options

What Happened

Nathan D. Jorgensen, Chief Financial Officer of Voyager Therapeutics (VYGR), received equity awards on February 6, 2026: 32,250 restricted stock units (RSUs) and a derivative grant covering 150,500 shares in the form of stock options. Both grants were reported as acquisitions at $0.00 (typical for compensation awards) in the Form 4 filed on February 10, 2026. These are grants/awards (code A), not purchases or sales.

Key Details

Transaction date: February 6, 2026; Form 4 filed: February 10, 2026 (appears to be filed one business day late relative to the SEC’s 2-business-day Form 4 deadline).
RSUs: 32,250 RSUs; each unit converts to one share upon vesting. Vesting starts on the grant date and occurs over three years: 1/3 on the 1-year anniversary, then 1/3 each successive year (see footnote F1).
Options (derivative): 150,500 share option grant. Vesting starts on the grant date and vests monthly over four years: 1/48th after one month, then monthly thereafter (see footnote F2). The filing lists no exercise price or cash exchanged in the grant entry.
Shares owned after transaction: not disclosed in the provided filing excerpt.
No tax-withholding sales, cashless exercises, 10b5-1 plans, or other sale transactions were reported in this filing.

Context

These awards are standard executive compensation grants intended to retain and incentivize management; they do not represent an open-market purchase (a bullish signal) or a sale (a liquidity event). RSUs convert to common shares on vesting; options give the right to buy shares subject to exercise terms (exercise price not shown in the excerpt).

Form 4

Period: 2026-02-06

Chief Financial Officer

Transactions

Award
Common Stock
[F1]
2026-02-06+32,250→ 156,084 total
Award
Stock Option (Right to Buy)
[F2]
2026-02-06+150,500→ 150,500 total
Exercise: $3.68Exp: 2036-02-06→ Common Stock (150,500 underlying)

Footnotes (2)

[F1]Consists of shares of common stock issuable under an aggregate of 32,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
[F2]This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

Signature

/s/ Gregory Shiferman, as Attorney-in-Fact for Nathan D. Jorgensen|2026-02-10

1 file